A gap remains in the role of neoadjuvant therapy for patients with ILC.
Method
Single-institution retrospective review of patients with ILC who received neoadjuvant therapy between 2008 and 2019.
Results
141 patients met inclusion criteria: 71 neoadjuvant chemotherapy (NACT) and 70 neoadjuvant endocrine therapy (NET). 7/71 (9.9%) patients had a pCR following NACT compared to 1/70 (1.4%) with NET (P = .063). pCR was observed in 5/18 (27.8%) patients with Her2Neu-positive disease following NACT, compared to 2/53 (3.8%) with Her2Neu-negative disease (P = .01).
For luminal B tumors, median Ki-67 decrease was similar following NACT and NET (18.3 vs 16.3, P = .26).
T category decreased in 59 (42.1%) patients following neoadjuvant therapy, increased in 9 (6.4%), and was unchanged in 72 (51.4%). More patients had an increase (28.6%) than decrease (12.1%) in their N category, including 13/60 (21.7%) who were clinically node-negative at diagnosis and identified to have node-positive disease following neoadjuvant therapy, at definitive surgery.
Conclusion
In Her2Neu-negative ILC, the potential of a pCR with NACT or NET is low. Most patients’ nodal status and tumor size remain unchanged. There is a potential for pathologic stage to be higher at surgery compared to the clinical stage prior to neoadjuvant therapy.
ChristopherLi 1IAndersonBOR DalingJMoeRE. Trends in incidence rates of invasive lobular and ductal breast. JAMA. 2003;289(11):1421-1424.
2.
Sastre-GarauXJouveMAsselainB, et al.Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996;77(1):113-120.
3.
ReedAEMKutasovicJRLakhaniSRSimpsonPT. Invasive lobular carcinoma of the breast: Morphology, biomarkers and ’omics. Breast Cancer Res. 2015;17:12.
4.
PetruoloOAPilewskieMPatilS, et al.Standard pathologic features can be used to identify a subset of estrogen receptor-positive, HER2 negative patients likely to benefit from neoadjuvant chemotherapy. Ann Surg Oncol. 2017;24:2556-2562.
5.
van de WaterWFonteinDBvan NesJG, et al.Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer – A TEAM study analysis. Eur J Cancer. 2012;49(2):297-304.
6.
PetrelliFBarniS. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: A meta-analysis of published trials including 1, 764 lobular breast cancer. Breast Cancer Res Treat. 2013;142(2):227-235.
7.
DixonJMRenshawLDixonJThomasJ. Invasive lobular carcinoma: Response to neoadjuvant letrozole therapy. Breast Cancer Res Treat. 2011;130(3):871-877.
8.
ThorntonMJWilliamsonHVWestbrookKE, et al.Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma. Ann Surg Oncol. 2019;26(10):3166-3177.
9.
ArthurLMTurnbullAKWebberVL, et al.Molecular changes in lobular breast cancers in response to endocrine therapy. Cancer Res. 2014;74(19):5371-5376.
10.
GoldhirschAWinerECoatesA, et al.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 2013;24(9):2206-2223.
11.
SymmansWFPeintingerFHatzisC, et al.Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-4422.
12.
GoncalvesRDeSchryverKMaC, et al.Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res Treat. 2017;165(2):355-364.
13.
RibaLARussellTAlapatiADavisRBJamesTA. Characterizing response to neoadjuvant chemotherapy in invasive lobular breast carcinoma. J Surg Res. 2019;233:436-443.
14.
LoiblSVolzCMauC, et al.Response and prognosis after neoadjuvant chemotherapy in 1, 051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 2014;144(1):153-162.
15.
DelpechYCoutantCHsuL, et al.Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer. 2013;108(2):285-291.
16.
EllisMJTaoYLuoJ, et al.Outcome prediction for estrogen receptor–positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. JNCI (J Natl Cancer Inst) : J Natl Cancer Inst. 2008;100(19):1380-1388.
17.
YauCvan der NoordaaMShadS, et al.Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149-160.
18.
MorrowELanniganADoughtyJ, et al.Population-based study of the sensitivity of axillary ultrasound imaging in the preoperative staging of node-positive invasive lobular carcinoma of the breast. Br J Surg. 2018;105(8):987-995.
19.
ChungHLTsoHHMiddletonLPSunJLeungJWT. Axillary nodal metastases in invasive lobular carcinoma versus invasive ductal carcinoma: Comparison of node detection and morphology by ultrasound. AJR Am J Roentgenol. 2022;218(1):33-41.
20.
KimSYKimEKMoonHJYoonJHKimMJ. Is pre-operative axillary staging with ultrasound and ultrasound-guided fine-needle aspiration reliable in invasive lobular carcinoma of the breast?Ultrasound Med Biol. 2016;42(6):1263-1272.
21.
BougheyJCMiddletonLPHarkerL, et al.Utility of ultrasound and fine-needle aspiration biopsy of the axilla in the assessment of invasive lobular carcinoma of the breast. Am J Surg. 2007;194(4):450-455.
22.
AbelMKGreenwoodHKelilT, et al.Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma. NPJ breast cancer. 2021;7(1):25-25.
23.
BougheyJCWagnerJGarrettBJ, et al.Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol. 2009;16(6):1606-1611.
24.
FitzalFMittlboeckMStegerG, et al.Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients. Ann Surg Oncol. 2011;19(2):519-526.
25.
MukhtarRAHoskinTLHabermannEBDayCNBougheyJC. Changes in management strategy and impact of neoadjuvant therapy on extent of surgery in invasive lobular carcinoma of the breast: Analysis of the national cancer database (NCDB). Ann Surg Oncol. 2021;28(11):5867-5877.
26.
HofmannDNitzUGluzO, et al.WSG ADAPT—adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: Study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial. Trials. 2013;14:261.
